Business Wire

OWL-LABS

4.6.2024 15:31:27 CEST | Business Wire | Press release

Share
Owl Labs Launches Meeting Owl® 4+ Camera and AI-Powered Software to Create the First Standalone 360-Degree, Wirelessly Connected Device System for Hybrid Work

Owl Labs, the first company to build AI-powered, 360-degree video conferencing solutions, today launched its next-generation flagship product, the Meeting Owl 4+. It is Owl Labs’ newest all-in-one, 360-degree camera, speaker, and mic device with 4K Ultra HD video for crystal clear video that’s sharper than ever. The new Meeting Owl is powered by the latest Owl Intelligence System (OIS) Software which now allows for wirelessly pairing more devices, so organisations can customise their spaces to meet their evolving needs.

Over 200,000 organisations across nearly 50 countries, from small businesses to 89 companies on the Fortune 100 list to educational institutions, have used Owl Labs products to power millions of hybrid experiences. Owl devices use robotics and proprietary, patented AI-powered software to automatically switch between cameras to capture the best view of in-room attendees, enabling natural, face-to-face conversations that transcend physical distance. With the introduction of the Meeting Owl 4+, Owl Labs now offers enhanced capabilities to more audiences, from small and medium-sized businesses (SMBs) to larger enterprises. In addition to pairing with more devices to cover larger spaces, the Meeting Owl 4+ has several other enterprise-friendly features, including easier fleet management for IT teams and customisable lighting and sound options upon startup.

With the latest AI-powered OIS software, the Meeting Owl 4+ pairs with Owl Labs’ customisable connected device system to capture all angles of the discussion. Owl Labs products can connect with others in over 25 different setup configurations, with both centre-of-room and front-and-centre options. For example, a company can wirelessly connect two Meeting Owls for greater coverage, or a Meeting Owl and an Owl BarTM to ensure all angles are covered, creating a full-room solution. The software is developed in the U.S. by an experienced team of engineers who are continually iterating to make Owl products smarter over time. All software adheres to industry-standard security protocols and Owl devices connect via a private, dedicated wireless network.

This launch is the latest advancement in Owl Labs’ mission to make hybrid meetings more inclusive and collaborative by leveling the playing field between remote and in-room participants. Hundreds of thousands of workplaces have moved beyond traditional conference room setups with equipment permanently mounted to walls and transitioned to user-friendly, plug-and-play Owl products with the flexibility, portability, and affordability that modern distributed offices need. Any type of meeting, in any size room, is covered with Owl Labs’ tailored technology, from sit-down roundtables to stand-up presentations to brainstorms on whiteboards. As companies grow, their video conferencing infrastructure adapts and expands with them. However, a vast market opportunity remains as Owl Labs’ State of Hybrid Work report found only 37% of employers upgraded their video meeting technology in the past year.

“Non-verbal communication is crucial in the workplace for collaboration and rapport, and studies have even shown that non-verbal communication is at least as important as verbal discussion, if not more,” said Frank Weishaupt, CEO of Owl Labs. “As the hybrid workplace has evolved beyond meetings where everyone is in the same room, we need to do away with outdated video technology that doesn't allow remote attendees to clearly see and hear during meetings. Meanwhile, today’s enterprise businesses are evolving their offices and processes faster than ever to keep up with the pace of economic and AI-driven transformation. At Owl Labs, we’re building easy-to-use meeting technology that’s as nimble as they are, from small businesses to the largest enterprises.”

The flexible, plug-and-play Meeting Owl 4+ is enterprise-ready and takes less than six minutes to set up. Features include:

  • Upgraded video quality: The 64-megapixel camera and sensor streams 4K Ultra HD video within a 10-foot radius.
  • Wide-range audio: Powerful, 360-degree speakers and smart mics have an 18-foot pickup radius. Extend the audio range even farther with the new matching, charcoal Expansion Mic.
  • Easy enterprise fleet management: IT administrators can seamlessly manage their fleet of Owl Labs devices from The Nest management tool, including bulk registration, default settings, and more.

The upgraded OIS software includes:

  • Silent Switching: When devices are paired, the technology detects where people are facing even when they’re not speaking, then seamlessly switches to the correct camera with the best view.
  • Quick and easy setup: Pair devices quickly, effortlessly and efficiently.
  • Platform-agnostic: Compatible with Microsoft Teams, Zoom, Google Meet, Slack, and other video conferencing platforms.
  • Improved Front + Centre Experience: Front + Centre experience upgrades introduce more accurate intelligent camera switching whether a participant is actively speaking or silently contributing to ensure the best angle is captured at all times.

The new Meeting Owl 4+ is launching in the United States, Canada and Europe. Customers in the UK can now purchase it for £1,999 / €2,199 (including VAT) through OwlLabs.com, Amazon, or third-party resellers and distribution partners. Find your local reseller or contact sales@owllabs.com.

To see video of the Meeting Owl 4+ in action, purchase other Owl Labs products or ensure your devices have the latest OIS software, visit owllabs.co.uk.

About Owl Labs:

Owl Labs is the first company to build AI-powered, 360-degree video conferencing solutions for hybrid organisations. Its connected device system and Owl Intelligence System™ software make meetings more inclusive and collaborative by leveling the playing field between remote and in-room participants. The Meeting Owl® 4+ is the latest generation of the first WiFi-enabled, 360-degree camera, microphone and speaker that automatically zooms in on whoever’s speaking. Owl Labs has raised £36.8 million in funding and is based in Boston, with remote and hybrid employees all over the world. To learn more and explore the company’s research on the State of Hybrid Work, visit OwlLabs.co.uk.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240531450854/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye